GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

The treatment strategy in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is shifting toward newer agents in the first line setting, while the existing roadmap in ROS1(+) NSCLC is not mature yet. The current NCCN recommendations categories alectinib as the preferred 1st line therapy for ALK(+) and crizotinib for ROS1(+) NSCLC. The ALEX 1,2,3 and the ALTA 4 studies indicates better progression free survival (PFS) when choosing second generation ALK tyrosine kinase inhibitors (TKI) as first line therapy compared with crizotinib.

Source: Lung Cancer - July 26, 2020 Category: Cancer & Oncology Authors: Nir Peled, Roni Gillis, Saadettin Kilickap, Patrizia Froesch, Sergei Orlov, Elena Filippova, Umut Demirci, Petros Christopoulos, Irfan Cicin, Fatma Bugdayci Basal, Cengiz Yilmaz, Moiseenko Fedor, Taner Korkmaz, Semra Paydas, Oliver Gautschi, Alisan Zirtil Source Type: research